All posts

Columbia Care stock is a buy post Cresco, Roth says

In the post-Cresco Labs era, Columbia Care (Columbia Care Stock Quote, Chart, News, Analysts, Financials CSE:CCHW) is still a buy, says Roth MKM analyst Scott Fortune.

On July 31, Cresco Labs and Columbia Care mutually decided to call off their proposed merger.

“In light of the evolving landscape in the cannabis industry, we believe the decision to terminate the planned transaction is in the long-term interest of Cresco Labs and our shareholders. We want to express our sincere gratitude to Columbia Care for their valuable collaboration and dedication during this transaction,” said Cresco CEO Charles Bachtell.

The Roth analyst says that in light of that development, CCHW is now free to shore up its own balance sheet.

“CCHW management was planning on addressing its balance sheet earlier, but was held up due to the pending Cresco Lab merger,” Fortune explained. “Now operating as a standalone business, the company was able to execute on equitizing a significant portion of its debt, while raising $25M (option to add
$25M) to further reduce leverage, capitalizing on the recent runup of its stock (up over 200%) over the past month. Given the ~29 month drawdown across the cannabis industry, we believe the recent runup will allow levered companies to address these debt positions and provides another avenue to raise capital for long-term survival, despite the dilution.”

In a research update to clients September 20, Fortune maintained his “Buy” rating and one-year price target of $1.00 on Columbia Care.

The analyst thinks CCHW will post EBITDA of $81.7-million on revenue of $520.3-million in fiscal 2023. He expects those numbers will improve to EBITDA of $107.2-million on a topline of $565.5-million the following year.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: cchw
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

Should you buy Trulieve ahead of Q2 results?

Ahead of the company's second quarter results, due August 6, Beacon Securities analyst Russell Stanley says you should be buying… [Read More]

6 hours ago

Ispire is my best stock idea, this analyst says

As we transition into the second half of 2024, Roth MKM Managing Director Scott Fortune's eyes are on one stock… [Read More]

11 hours ago

Is RIOT stock a buy? (July, 2024)

Crypto is set to rise and the best way to play it is Riot Platforms (Riot Platforms Stock Quote, Chart,… [Read More]

1 day ago

Will smallcap stocks ever break out?

If you own the FAANG stocks you have been happy. But if you prefer to not own megacap equities it… [Read More]

2 days ago

Is IMAX stock a buy? (July, 2024)

With an improving international footprint, Roth MKM analyst Eric Handler thinks there is money to be made on IMAX (IMAX… [Read More]

5 days ago

Quipt Home Medical a “Top Pick” at Ventum

With its stock on an extended slide, Ventum Capital Markets analyst Stefan Quenneville thinks there is money to be made… [Read More]

5 days ago